Loading clinical trials...
Loading clinical trials...
A Phase 3 Open-Label, Single-Arm Study to Evaluate the Safety and Immunogenicity of a JN.1 Subvariant SARS CoV-2 rS Vaccine
Conditions
Interventions
NVX-CoV2705 Vaccine
Locations
2
United States
Foothills Research Center - CCT Research
Phoenix, Arizona, United States
Benchmark Research
Austin, Texas, United States
Start Date
October 14, 2024
Primary Completion Date
October 15, 2024
Completion Date
April 17, 2025
Last Updated
July 18, 2025
Lead Sponsor
Novavax
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions